DVAX vs. ALKS, IONS, FOLD, LGND, BCRX, GERN, MNKD, CLDX, NVAX, and INVA
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Geron (GERN), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
Dynavax Technologies vs.
Alkermes (NASDAQ:ALKS) and Dynavax Technologies (NASDAQ:DVAX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
In the previous week, Alkermes had 3 more articles in the media than Dynavax Technologies. MarketBeat recorded 20 mentions for Alkermes and 17 mentions for Dynavax Technologies. Alkermes' average media sentiment score of 0.40 beat Dynavax Technologies' score of -0.09 indicating that Alkermes is being referred to more favorably in the media.
Alkermes presently has a consensus price target of $38.36, indicating a potential upside of 8.07%. Dynavax Technologies has a consensus price target of $21.50, indicating a potential upside of 61.23%. Given Dynavax Technologies' higher probable upside, analysts plainly believe Dynavax Technologies is more favorable than Alkermes.
Alkermes has a net margin of 23.57% compared to Dynavax Technologies' net margin of 7.85%. Alkermes' return on equity of 30.80% beat Dynavax Technologies' return on equity.
95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 3.0% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Alkermes received 228 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.52% of users gave Alkermes an outperform vote while only 65.79% of users gave Dynavax Technologies an outperform vote.
Alkermes has higher revenue and earnings than Dynavax Technologies. Alkermes is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Alkermes has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
Summary
Alkermes beats Dynavax Technologies on 13 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 2/21/2025 by MarketBeat.com Staff
